Steven A. Smith, MD
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0217.
Requests for Single Reprints: Steven A. Smith, MD, Mayo College of Medicine, 200 First Street SE, Rochester, MN 55905; e-mail, mailto:firstname.lastname@example.org.
Smith SA. Still Uncertain About Sodium–Glucose Cotransporter Inhibitors Despite 2 Centuries of Study. Ann Intern Med. 2012;156:466-467. doi: 10.7326/0003-4819-156-6-201203200-00012
Download citation file:
Published: Ann Intern Med. 2012;156(6):466-467.
Dapagliflozin, the first in the class of selective renal sodium–glucose cotransporter (SGLT) inhibitors (1), offers a novel, insulin-independent mechanism of action for diabetes treatment. Nonselective SGLT inhibitors block adenosine triphosphate–dependent, sodium-linked facilitated transport of glucose across the brush border cells of the small intestine (isoform SGLT1) and renal tubular epithelium (dominantly isoform SGLT2), leading to decreased intestinal absorption and renal tubular resorption of glucose (2). Although SGLT inhibitors may represent a new class of drugs for managing hyperglycemia and possibly obesity, the understanding of the SGLT system, cellular glucose transport, and the ability to induce glycosuria as a potential management option for type 2 diabetes has been evolving over the past 2 centuries (3–5).
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Hematology/Oncology, Nephrology, Diabetes.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only